Ablative Solutions has announced that it has added Paul Sobotka, a highly respected clinician, to its Scientific Advisory Board. The company is developing a patented device for sympathetic nerve modulation, the Peregrine System, which delivers treatment to the outer region of arteries, including renal arteries, where the sympathetic nerves are located. The interruption of these nerve pathways may have therapeutic implications for hypertension, metabolic syndrome, congestive heart failure and obesity.
Paul Sobotka, is clinical professor of medicine/cardiology at Ohio State University and is an expert in sympathetic nerve modulation and hypertension, having served as chief medical officer at Ardian, and having played a very active role in basic and clinical research in this field. “Ablative Solutions has assembled an exceptional group of scientific advisors with a long track record of innovation, and I am honoured to be a part of this creative group,” states Sobotka. “Combining the Peregrine System technology with this dynamic Ablative Solutions team is exciting. I am confident that we can create new products that will address our patients’ healthcare needs and improve the choices available to safely and effectively treat their chronic illnesses.”
Sobotka joins a distinguished Scientific Advisory Board that includes:
— William Abraham, chief of Cardiovascular Medicine, Ohio State
University
— Steven Almany, medical director of Beaumont Hospital
System, associate professor, Beaumont Oakland University School of
Medicine, Rochester, USA
— Maurice Buchbinder, Foundation for Cardiovascular Medicine,
San Diego, USA
— Dean Kereiakes, medical director, The Christ Hospital
Heart and Vascular Center and The Carl and Edyth Lindner Center for
Research and Education at The Christ Hospital, Cincinnati, USA
— R. Stefan Kiesz, president & chief executive officer, San Antonio
Endovascular & Heart Institute; Co-Founder, American Heart of Poland
— Robert Schwartz, professor of medicine, University of
Minnesota, cardiologist at Minneapolis Heart Institute
“We are honoured to have Dr. Sobotka join our esteemed group of scientific and clinical advisors,” said Tim Fischell, chief executive officer of Ablative Solutions. “This visionary group’s track record in exploring ways to improve therapy will play a vital role as we investigate the diseases that might benefit from sympathetic nerve modulation via perivascular chemical denervation with the Peregrine System.”
ASI was founded by two proven medical device entrepreneurs, Tim Fischell, and David Fischell. Development efforts have been led by ASI president, Vartan Ghazarossian, whose executive experience in both biopharmaceutical and medical device companies has added significant value to novel device-chemistry combination therapy. The Peregrine System uses a unique, patent-pending technology to deliver diagnostic and therapeutic agents directly to the perivascular layer that surrounds blood vessels.
